Unicycive Therapeutics, Inc. (UNCY)
$0.5284
-0.00 (-0.30%)
Rating:
Recommendation:
-
| Symbol | UNCY |
|---|---|
| Price | $0.5284 |
| Beta | 2.627 |
| Volume Avg. | 0.05M |
| Market Cap | 18.364M |
| Shares () | - |
| 52 Week Range | 0.4-2.87 |
| 1y Target Est | - |
| DCF Unlevered | UNCY DCF -> | |
|---|---|---|
| DCF Levered | UNCY LDCF -> | |
| ROE | -762.51% | Strong Sell |
| ROA | -199.19% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 25.22% | Neutral |
| P/E | -0.36 | Neutral |
| P/B | 5.02 | Strong Buy |
Latest UNCY news
About
Download (Excel)Dr. Shalabh K. Gupta M.D., MPA
Healthcare
Biotechnology
NASDAQ Capital Market
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.